Seminars in Nephrology
Volume 25, Issue 4 , Pages 215-226 , July 2005

Clinical Pharmacology of Antihypertensive Therapy

  • Addison A. Taylor

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Addison A. Taylor, MD, PhD, Section on Hypertension and Clinical Pharmacology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
    • ,
  • James L. Pool

References 

  1. Chobanian A , Bakris GL , Black HR , et al.   The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (The JNC 7 report) . JAMA . 2003;289:2560–2572
  2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)) . JAMA . 2002;288:2981–2997
  3. Cushman WC , Ford CE , Cutler JA , et al.   Success and predictors of blood pressure control in diverse North American settings (The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)) . J Clin Hypertens (Greenwich) . 2002;4:393–404
  4. De Jong PE , Navis G , de ZD . Renoprotective therapy (Titration against urinary protein excretion) . Lancet . 1999;354:352–353
  5. Weinberg MS , Kaperonis N , Bakris GL . How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? . Curr Hypertens Rep . 2003;5:418–425
  6. Morledge JH , Ettinger B , Aranda J , et al.   Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone . J Am Geriatr Soc . 1986;34:199–206
  7. Franse LV , Pahor M , Di BM , et al.   Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program . Hypertension . 2000;35:1025–1030
  8. Psaty BM , Smith NL , Siscovick DS , et al.   Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis . JAMA . 1997;277:739–745
  9. Franse LV , Pahor M , Di Bari M , et al.   Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program . Hypertension . 2000;35:1025–1030
  10. Flack JM , Saunders E , Gradman A , et al.   Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension . Clin Ther . 2001;23:1193–1208
  11. Materson BJ , Reda DJ , Cushman WC , et al.  The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents   Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo . N Engl J Med . 1993;328:914–921
  12. Materson BJ , Reda DJ , Cushman WC  Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents . Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data . Am J Hypertens . 1995;8:189–192
  13. Materson BJ , Reda DJ , Preston RA , et al.  Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents   Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug . Arch Intern Med . 1995;155:1757–1762
  14. Tarazi RC , Dustan HP , Frohlich ED . Long-term thiazide therapy in essential hypertension (Evidence for persistent alteration in plasma volume and renin activity) . Circulation . 1970;41:709–717
  15. Psaty BM , Lumley T , Furberg CD , et al.   Health outcomes associated with various antihypertensive therapies used as first-line agents (A network meta-analysis) . JAMA . 2003;289:2534–2544
  16. Vidt DG . The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure . Cleve Clin J Med . 2003;70:263–269
  17. Pollare T , Lithell H , Berne C . A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension . N Engl J Med . 1989;321:868–873
  18. Cardinal H , Monfared AA , Dorais M , et al.   A comparison between persistence to therapy in ALLHAT and in everyday clinical practice (A generalizability issue) . Can J Cardiol . 2004;20:417–421
  19. Lindholm LH , Persson M , Alaupovic P , et al.   Metabolic outcome during 1 year in newly detected hypertensives (Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)) . J Hypertens . 2003;21:1563–1574
  20. Verdecchia P , Reboldi G , Angeli F , et al.   Adverse prognostic significance of new diabetes in treated hypertensive subjects . Hypertension . 2004;43:963–969
  21. Sica DA . Current concepts of pharmacotherapy in hypertension: Diuretic-related side effects: Development and treatment . J Clin Hypertens (Greenwich) . 2004;6:532–540
  22. Carter BL , Ernst ME , Cohen JD . Hydrochlorothiazide versus chlorthalidone (Evidence supporting their interchangeability) . Hypertension . 2004;43:4–9
  23. Soriano JB , Hoes AW , Meems L , et al.   Increased survival with beta-blockers (Importance of ancillary properties) . Prog Cardiovasc Dis . 1997;39:445–456
  24. Freemantle N , Cleland J , Young P , et al.   Beta blockade after myocardial infarction (Systematic review and meta regression analysis) . BMJ . 1999;318:1730–1737
  25. Brewster LM , van Montfrans GA , Kleijnen J . Systematic review (Antihypertensive drug therapy in black patients) . Ann Intern Med . 2004;141:614–627
  26. Yancy CW , Laskar S , Eichhorn E . The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure . Congest Heart Fail . 2004;10:34–37
  27. Grossman E , Messerli FH . Why beta-blockers are not cardioprotective in elderly patients with hypertension . Curr Cardiol Rep . 2002;4:468–473
  28. Messerli FH , Grossman E , Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?. A systematic review . JAMA . 1998;279:1903–1907
  29. Cazzola M , Noschese P , D’Amato G , et al.   The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction . Chest . 2002;121:230–241
  30. Salpeter SR , Ormiston TM , Salpeter EE . Cardioselective {beta}-blockers in patients with reactive airway disease (A meta-analysis) . Ann Intern Med . 2002;137:715–725
  31. Ormiston TM , Salpeter SR . Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease (Moving from myth to evidence-based practice) . Heart Fail Monit . 2003;4:45–54
  32. Carlberg B , Samuelsson O , Lindholm LH . Atenolol in hypertension (Is it a wise choice?) . Lancet . 2004;364:1684–1689
  33. Kizer JR , Dahlof B , Kjeldsen SE , et al.   Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol (The Losartan Intervention For Endpoint reduction in hypertension study) . Hypertension . 2005;45:46–52
  34. Hockerman GH , Peterson BZ , Johnson AB , et al.   Molecular determinants of drug binding and action on L-type calcium channels . Ann Rev Pharmacol Toxicol . 1997;37:361–396
  35. Saseen JJ , Carter BL , Brown TE , et al.   Comparison of nifedipine alone and with diltiazem or verapamil in hypertension . Hypertension . 1996;28:109–114
  36. Held PH , Yusuf S , Furberg CD . Calcium channel blockers in acute myocardial infarction and unstable angina (An overview) . BMJ . 1989;299:1187–1192
  37. Zhang X , Hintze TH . Amlodipine releases nitric oxide from canine coronary microvessels (An unexpected mechanism of action of a calcium channel-blocking agent) . Circulation . 1998;97:576–580
  38. Zhang XP , Loke KE , Mital S , et al.   Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine . J Cardiovasc Pharmacol . 2002;39:208–214
  39. Zhang X , Xu X , Nasjletti A , et al.   Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels . J Cardiovasc Pharmacol . 2000;35:195–202
  40. Abernethy DR , Schwartz JB . Calcium-antagonist drugs . N Engl J Med . 1999;341:1447–1457
  41. Cushman WC . Are there benefits to specific antihypertensive drug therapy? . Am J Hypertens . 2003;16:31S–35S
  42. Cai H , Harrison DG . Endothelial dysfunction in cardiovascular diseases (The role of oxidant stress) . Circ Res . 2000;87:840–844
  43. Irvin JD , Viau JM . Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril . Am J Med . 1986;81:46–50
  44. Dzau VJ , Bernstein K , Celermajer D , et al.   Pathophysiologic and therapeutic importance of tissue ACE (A consensus report) . Cardiovasc Drugs Ther . 2002;16:149–160
  45. Elliott WJ . Optimizing medication adherence in older persons with hypertension . Int Urol Nephrol . 2003;35:557–562
  46. Bakris GL , Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine (Is this a cause for concern?) . Arch Intern Med . 2000;160:685–693
  47. Ferdinand KC . Recommendations for the management of special populations (Racial and ethnic populations) . Am J Hypertens . 2003;16:50S–54S
  48. Israili ZH , Hall WD . Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology . Ann Intern Med . 1992;117:234–242
  49. Trifilieff A , Da Silva A , Gies JP . Kinins and respiratory tract diseases . Eur Respir J . 1993;6:567–587
  50. Boulet LP , Milot J , Lampron N , et al.   Pulmonary function and airway responsiveness during long-term therapy with captopril . JAMA . 1989;261:413–416
  51. Gibbs CR , Lip GY , Beevers DG . Angioedema due to ACE inhibitors (Increased risk in patients of African origin) . Br J Clin Pharmacol . 1999;48:861–865
  52. Brown NJ , Ray WA , Snowden M , et al.   Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema . Clin Pharmacol Ther . 1996;60:8–13
  53. Gregory KW , Davis RC . Images in clinical medicine. Angioedema of the intestine . N Engl J Med . 1996;334:1641
  54. Pryde PG , Sedman AB , Nugent CE , et al.   Angiotensin-converting enzyme inhibitor fetopathy . J Am Soc Nephrol . 1993;3:1575–1582
  55. Lambot MA , Vermeylen D , Noel JC . Angiotensin-II-receptor inhibitors in pregnancy . Lancet . 2001;357:1619–1620
  56. White WB , Kent J , Taylor A , et al.   Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors . Hypertension . 2002;39:929–934
  57. Izhar M , Alausa T , Folker A , et al.   Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics . Hypertension . 2004;43:573–577
  58. Israili ZH . Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension . J Hum Hypertens . 2000;14(suppl 1):S73–S86
  59. Oparil S . Newly emerging pharmacologic differences in angiotensin II receptor blockers . Am J Hypertens . 2000;13:18S–24S
  60. Stangier J , Su CA , Hendriks MG , et al.   The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers . J Clin Pharmacol . 2000;40:1373–1379
  61. Gardner SF , Franks AM . Olmesartan medoxomil (The seventh angiotensin receptor antagonist) . Ann Pharmacother . 2003;37:99–105
  62. Sica DA , Gehr TW . The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease . J Renin Angiotensin Aldosterone Syst . 2002;3:247–254
  63. Pool JL . Doxazosin (A new approach to hypertension and benign prostatic hyperplasia) . Br J Clin Pract . 1996;50:154–163
  64. Pool JL , Taylor AA , Nelson EB . Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension . Am J Med . 1989;87:57S–61S
  65. McInnes GT . The value of alpha-blockers in the management of hypertension (A practical view) . J Hum Hypertens . 1991;5:313–316
  66. Sica DA . Minoxidil (An underused vasodilator for resistant or severe hypertension) . J Clin Hypertens (Greenwich) . 2004;6:283–287
  67. Taylor AL , Ziesche S , Yancy C , et al.   Combination of isosorbide dinitrate and hydralazine in blacks with heart failure . N Engl J Med . 2004;351:2049–2057
  68. Carson P , Ziesche S , Johnson G , et al.  Vasodilator-Heart Failure Trial Study Group   Racial differences in response to therapy for heart failure (analysis of the vasodilator-heart failure trials) . J Card Fail . 1999;5:178–187
  69. Reece PA , Zacest R . Hydralazine . In:  Messerli FH editors. Cardiovascular Drug Therapy . Philadelphia: WB Saunders; 1990;p. 834–848
  70. Sica DA , Gehr TW . Direct vasodilators and their role in hypertension management (Minoxidil) . J Clin Hypertens (Greenwich) . 2001;3:110–114
  71. Ausubel H , Levine ML . Treatment of hypertension with Ser-Ap-Es . Curr Ther Res Clin Exp . 1967;9:29–35
  72. Ellershaw DC , Gurney AM . Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery . Br J Pharmacol . 2001;134:621–631
  73. Schwartz GL , Turner ST . Pharmacogenetics of antihypertensive drug responses . Am J Pharmacogenomics . 2004;4:151–160
  74. Oelke K , Richardson B . Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression . Int Rev Immunol . 2004;23:315–331
  75. Cameron HA , Ramsay LE . The lupus syndrome induced by hydralazine (A common complication with low dose treatment) . BMJ . 1984;289:410–412
  76. Campese VM . Minoxidil . In:  Messerli FH editors. Cardiovascular Drug Therapy . Philadelphia: WB Saunders; 1990;p. 849–860
  77. Parish JL , Hughes MA , Cherry GW , et al.   The effect of minoxidil analogues and metabolites on the contraction of collagen lattices by human skin fibroblasts . Br J Plast Surg . 1995;48:154–160
  78. Holland OB , von KL , Campbell WB , et al.   Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients . Hypertension . 1983;5:235–239
  79. Julius S , Alderman M , Beevers G , et al.   Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy (The life study) . J Am Coll Cardiol . 2004;43:1047–1055
  80. Juurlink DN , Mamdani MM , Lee DS , et al.   Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study . N Engl J Med . 2004;351:543–551
  81. Jamerson KA , Nwose O , Jean-Louis L , et al.   Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension . Am J Hypertens . 2004;17:495–501
  82. Neutel JM , Smith DHG . Effects of fixed, low-dose combination amlodipine/benazepril therapy vs component monotherapy on systolic blood pressure (Results of the SELECT (systolic evaluation of Lotrel efficacy and comparative therapies) trial) . Am J Hypertens . 2003;16:196A
  83. Neutel JM , Smith DHG , Weber MA . Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass . Am J Hypertens . 2004;17:37–42
  84. Agodoa LY , Appel L , Bakris GL , et al.   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis (A randomized controlled trial) . JAMA . 2001;285:2719–2728
  85. Wright JT , Bakris GL , Greene T , et al.   Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease (Results from the AASK trial) . JAMA . 2002;288:2421–2431
  86. Bakris GL , Weir MR , Dequattro V , et al.   Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy . Kidney Int . 1998;54:1283–1289
  87. Lash JP , Bakris GL . Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy . Nephrol Dial Transplant . 1995;10(suppl 9):56–62
  88. Boero R , Rollino C , Massara C , et al.   The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study . Am J Kidney Dis . 2003;42:67–75
  89. Messerli FH . Vasodilatory edema (A common side effect of antihypertensive therapy) . Curr Cardiol Rep . 2002;4:479–482
  90. Nishizaka MK , Zaman MA , Calhoun DA . Efficacy of low-dose spironolactone in subjects with resistant hypertension . Am J Hypertens . 2003;16:925–930
  91. Physician’s Desk Reference . Montvale, NJ: Thompson PDR; 2005;

PII: S0270-9295(05)00031-8

doi: 10.1016/j.semnephrol.2005.02.006

Seminars in Nephrology
Volume 25, Issue 4 , Pages 215-226 , July 2005

Article Tools

* Image Usage & Resolution